News & Updates
Filter by Specialty:
Growth hormone reduces liver fat, fibro-inflammation in obese/overweight adults with NAFLD
In adults with overweight/obesity and nonalcoholic fatty liver disease (NAFLD), daily administration of growth hormone (GH) reduced hepatic steatosis and improved markers of hepatic inflammation and fibrosis, a study has shown.
Growth hormone reduces liver fat, fibro-inflammation in obese/overweight adults with NAFLD
27 Jul 2022
Abdominal aortic calcification linked to CAD, CI in T2DM
In patients with type 2 diabetes mellitus (T2DM), abdominal aortic calcification might be an important indicator of coronary artery disease (CAD) and cerebral infarction (CI), a new study has found.
Abdominal aortic calcification linked to CAD, CI in T2DM
26 Jul 2022
Empagliflozin shows promise for chronic SIAD-induced hyponatremia
The sodium-glucose cotransporter 2 inhibitor empagliflozin showed potential as a treatment alternative for hyponatremia due to chronic syndrome of inadequate antidiuresis (SIAD), according to a trial presented at ENDO 2022.
Empagliflozin shows promise for chronic SIAD-induced hyponatremia
26 Jul 2022
Obese/overweight patients incur 10 percent long-term weight loss with lifestyle management, medication
Individuals who are overweight or obese can achieve an approximately 10 percent weight loss over 3–5 years with the use of anti-obesity medications in addition to lifestyle management, according to a retrospective study presented at ENDO 2022.
Obese/overweight patients incur 10 percent long-term weight loss with lifestyle management, medication
25 Jul 2022
Nutritional risk in older diabetes patients tied to diabetic retinopathy
A low geriatric nutritional risk index score seems to worsen the risk of proliferative diabetic retinopathy in older adults with type 2 diabetes, a recent study has found.
Nutritional risk in older diabetes patients tied to diabetic retinopathy
24 Jul 2022
Lower diabetes risk test cutoff ups lab cost, identifies more persons with prediabetes
Use of the American Diabetes Association (ADA) Diabetes Risk Test (DRT) cutoff score of 4 as part of an employee wellness screening program to identify individuals at risk for developing the disease adds up to laboratory costs, reports a study.
